利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.032 秒)

    NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES
    4.
    发明申请
    NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES 有权
    用于治疗MAMMALIAN LYSOSOMAL存储疾病的MAMMALIAN脐带干细胞的初步施用方法

    公开(公告)号：US20090016998A1

    公开(公告)日：2009-01-15

    申请号：US12168608

    申请日：2008-07-07

    申请人： Svitlana Garbuzova-Davis ,  Paul R. Sanberg ,  Sylvia Gografe

    发明人： Svitlana Garbuzova-Davis ,  Paul R. Sanberg ,  Sylvia Gografe

    IPC分类号： A61K35/12 ,  A61P43/00

    CPC分类号： A61K35/44

    摘要： A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.

    摘要翻译： 一种治疗怀疑患有涉及异常或缺失蛋白质的先天性病症的胎儿或胚胎的方法，具有以下步骤：a。 提供适合于静脉内施用形式的多种人脐带血; a b。 对携带怀疑有先天性胚胎的胎儿的母亲施用人脐带血细胞。 这种先天性病症包括Sanfilippo综合征，亨特综合征，赫勒勒综合征，泰萨克病，戈谢病，冯·吉尔克病，庞培病，康利病，安徒生病，麦卡德尔病，赫斯病，牛磺病或1型糖原贮积病。

    Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
    5.
    发明授权
    Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders 有权

    公开(公告)号：US11007230B1

    公开(公告)日：2021-05-18

    申请号：US15250239

    申请日：2016-08-29

    申请人： Svitlana Garbuzova-Davis ,  Jared Carl Ehrhart ,  Paul R. Sanberg

    发明人： Svitlana Garbuzova-Davis ,  Jared Carl Ehrhart ,  Paul R. Sanberg

    IPC分类号： A61K35/51 ,  A61K35/28 ,  A61K35/12

    摘要： Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. Increasing evidence shows autoimmune mechanisms likely promote disease progression. Human umbilical cord blood (hUCB) derived plasma is rich in cytokines and growth factors that are required for growth and survival of cells during hematopoiesis. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients.

    PLASMA DERIVED FROM HUMAN UMBILICAL CORD BLOOD FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
    6.
    发明申请
    PLASMA DERIVED FROM HUMAN UMBILICAL CORD BLOOD FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS 审中-公开

    公开(公告)号：US20200061123A1

    公开(公告)日：2020-02-27

    申请号：US16655506

    申请日：2019-10-17

    申请人： Svitlana Garbuzova-Davis ,  Jared Carl Ehrhart ,  Paul R. Sanberg

    发明人： Svitlana Garbuzova-Davis ,  Jared Carl Ehrhart ,  Paul R. Sanberg

    IPC分类号： A61K35/51 ,  A61P25/28 ,  C12N5/0775

    摘要： A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

    Method of prenatal administration of mammalian umbilical cord stem cells for the intrauterine treatment of sanfilippo syndrome
    7.
    发明授权
    Method of prenatal administration of mammalian umbilical cord stem cells for the intrauterine treatment of sanfilippo syndrome 有权
    哺乳动物脐带干细胞产前给药方法，用于子宫内膜治疗Sanfilippo综合征

    公开(公告)号：US09173907B2

    公开(公告)日：2015-11-03

    申请号：US12168608

    申请日：2008-07-07

    申请人： Svitlana Garbuzova-Davis ,  Paul R. Sanberg ,  Sylvia Gografe

    发明人： Svitlana Garbuzova-Davis ,  Paul R. Sanberg ,  Sylvia Gografe

    IPC分类号： A61K35/44

    CPC分类号： A61K35/44

    摘要： A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.

    摘要翻译： 一种治疗怀疑患有涉及异常或缺失蛋白质的先天性病症的胎儿或胚胎的方法，具有以下步骤：a。 提供适合于静脉内施用形式的多种人脐带血; a b。 对携带怀疑有先天性胚胎的胎儿的母亲施用人脐带血细胞。 这种先天性病症包括Sanfilippo综合征，亨特综合征，赫勒勒综合征，泰萨克病，戈谢病，冯·吉尔克病，庞培病，康利病，安徒生病，麦卡德尔病，赫斯病，牛磺病或1型糖原贮积病。